Disease-Modifying Treatment in Progressive Multiple Sclerosis
Purpose of review
Multiple sclerosis (MS) is an immune-mediated disorder that affects the central nervous system (CNS), often first affecting people in early adulthood. Although most MS patients have a relapsing-remitting course (RRMS) at disease onset, a substantial proportion later develop chronic progression, termed secondary progressive MS (SPMS). Approximately 10% of MS patients experience chronic progression from disease onset, termed primary progressive multiple sclerosis (PPMS). Although several disease-modifying treatment (DMT) options exist for relapsing forms of this disease, DMT options are few for progressive MS (PPMS and SPMS). Herein, we strive to define progressive MS, review major clinical trials aimed at progressive MS, and delineate potential strategies in the management of progressive MS.
In 2017, the first DMT for PPMS, the B lymphocyte-depleting monoclonal antibody, ocrelizumab, came to market. Ocrelizumab reduced 12-week confirmed disability progression (CDP) by 24% versus placebo. Siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month CDP by 21% versus placebo in SPMS. Ibudilast slowed brain atrophy in PPMS and SPMS patients in a multicenter phase 2b study. Smaller early phase studies of alpha-lipoic acid and simvastatin each found slowing of rate of whole brain atrophy in SPMS patients.
Reasons now exist for optimism in the search for DMTs for progressive MS. It remains a challenge to identify outcome measures that accurately reflect the underlying pathology in progressive MS, which is less inflammatory and more degenerative than RRMS.
KeywordsProgressive multiple sclerosis Disease-modifying therapy Neuroprotection Remyelination
Anne Haney Cross was supported in part by the Manny and Rosalyn Rosenthal–Dr. John L. Trotter MS Center Chair in Neuroimmunology of the Barnes-Jewish Hospital Foundation.
Compliance with Ethical Standards
Conflict of Interest
John Robert Ciotti declares no conflict of interest.
Anne Haney Cross reports personal fees from Abbvie, Biogen, Bayer Healthcare, EMD Serono, Genzyme (Sanofi), Genentech (Roche), Novartis, and Teva Neuroscience.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 9.• Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, et al. Defining secondary progressive multiple sclerosis. Brain. 2016;139:2395–405. Using computer-based analytics, this paper endeavors to create an objective definition of secondary progressive MS using a prospectively-collected database of MS patientsCrossRefPubMedGoogle Scholar
- 10.• Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015;14:208–23. This review of prior clinical trials in progressive MS also critically evaluates clinical trial design in this patient populationCrossRefPubMedPubMedCentralGoogle Scholar
- 15.British And Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet. 1988;332(8604):179–83.Google Scholar
- 16.The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet. 1991;337(8739):441–6.Google Scholar
- 25.Montalban X, et al. Efficacy of cladribine tablets as add-on to IFN-beta therapy in patients with active relapsing MS: final results from the phase II ONWARD study. Neurology. 2016;86(Supplement):P3.029.Google Scholar
- 27.Andersen O, Elovaara I, Färkkilä M, Hansen HJ, Mellgren SI, Myhr KM, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004;75:706–10.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.•• Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209–20. This phase 3 trial of ocrelizumab met its primary endpoint as well as several secondary endpoints, leading to its approval for PPMSCrossRefPubMedGoogle Scholar
- 35.Hartung HP, et al. ASCEND phase 3 trial open-label extension study results: natalizumab may delay disability progression in secondary progressive multiple sclerosis (SPMS). Neurology. 2017;88(Supplement):P5.330.Google Scholar
- 37.•• Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics. 2017;14:859–73. https://doi.org/10.1007/s13311-017-0565-4. This review of clinical trials of S1P receptor modulators reviews results of the phase 3 EXPAND trial of siponimod in SPMS.CrossRefPubMedGoogle Scholar
- 40.•• Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study. Mult Scler. 2016;22(13):1719–31. The results of this phase 3 trial of high-dose biotin in progressive MS patients demonstrated significant disability reversal in a small proportion of the treatment groupCrossRefPubMedPubMedCentralGoogle Scholar
- 41.•• Spain R, Powers K, Murchison C, Heriza E, Winges K, Yadav V, et al. Lipoic acid in secondary progressive MS. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e374. This phase 2 trial of alpha-lipoic acid in SPMS demonstrated 68% reduction in annualized percent change in brain volume versus placeboCrossRefPubMedPubMedCentralGoogle Scholar
- 42.•• Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014;383:2213–21. This phase 2 trial of simvastatin in SPMS showed 43% reduction in annualized percent change in brain volume versus placeboCrossRefPubMedGoogle Scholar
- 47.McCroskery P, et al. Safety and tolerability of opicinumab in relapsing multiple sclerosis: the phase 2b SYNERGY trial. Neurology. 2017;88(Supplement):P5.369.Google Scholar
- 50.Martinelli-Boneschi F, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013;5:CD002127.Google Scholar
- 65.Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, et al. A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. Mult Scler. 2015;21(7):885–93.CrossRefPubMedGoogle Scholar
- 72.Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017;390:2481–9. https://doi.org/10.1016/S0140-6736(17)32346-2.CrossRefPubMedGoogle Scholar
- 76.Volpe G, Bernstock JD, Peruzzotti-Jametti L, Pluchino S. Modulation of host immune responses following non-hematopoietic stem cell transplantation: translational implications in progressive multiple sclerosis. J Neuroimmunol. 2016; https://doi.org/10.1016/j.jneuroim.2016.12.005.